Avava Raises $30M Series B Led by Catalio Capital Management for Energy-Based Skin Devices

Avava Secures $30M Series B

Avava, a Boston-based medical aesthetics company, has raised $30 million in Series B funding. The round was led by Catalio Capital Management, which is the sole investor listed in the financing.

The capital comes as the company looks to expand its energy-based skin treatment platform across a global provider network and continue its international growth.

What Avava Does

Avava develops energy-based skin treatment devices built around its patented Focal Point Technology. According to the company, the technology delivers energy with precision while preserving surrounding tissue.

That precision-focused design is intended to enable highly customizable treatments across a broad range of skin types and body areas. The platform is supported by integrated cooling and a connected digital ecosystem for patients and providers.

The company is co-founded by dermatology researcher Dr. R. Rox Anderson and led by CEO Clint Carnell. Avava serves a global provider network and is expanding internationally.

The Technology Angle

In medical aesthetics, device differentiation often comes down to control: how precisely energy can be delivered, how much surrounding tissue is spared, and how well a treatment can be tuned to different patients and anatomical areas. Avava's Focal Point Technology is positioned squarely on those dimensions.

The addition of integrated cooling addresses a practical clinical consideration in energy-based treatments, while the connected digital ecosystem is aimed at both patients and providers — a combination that reflects the broader trend of aesthetics platforms pairing hardware with software-enabled workflow and engagement tools.

Why the Round Matters

A $30 million Series B led by Catalio Capital Management gives Avava capital to pursue its stated priorities: serving its global provider network and expanding internationally. Catalio's participation as lead signals continued investor interest in the medical aesthetics category, where device companies with differentiated technology and established clinical leadership can scale through provider networks.

The involvement of a co-founder with deep dermatology research credentials, alongside an experienced CEO, gives the company a combination of scientific grounding and commercial leadership as it moves into its next phase of growth.

Market Context

Medical aesthetics has remained an active area for device investment, driven by sustained patient demand for skin treatments and by providers seeking platforms that can address a wide range of skin types and body areas. Companies that can demonstrate customizable treatment profiles and reliable clinical performance are well positioned to compete for provider adoption.

Avava's emphasis on treating a broad range of skin types is notable in a category where device performance can vary across patient populations. If the company's precision delivery and cooling integration translate into consistent outcomes across diverse patients, that breadth becomes a meaningful commercial advantage as it expands into new geographies.

What to Watch

With $30 million in new funding and Catalio Capital Management leading the round, Avava's next milestones will center on international expansion and deepening penetration within its existing global provider network. The company's ability to scale its connected digital ecosystem alongside its device placements — and to demonstrate customizable treatment outcomes across skin types and body areas — will be key indicators of traction.

For strategics and investors tracking the medical aesthetics device space, Avava now enters its next stage of growth with fresh capital, a differentiated patented technology platform, and leadership anchored by both dermatological research and operating experience.